Fate therapeutics reports new employee inducement award under nasdaq listing rule 5635(c)(4)

San diego, march 05, 2024 (globe newswire) -- fate therapeutics, inc. (nasdaq: fate), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (ipsc)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the company granted a non-qualified stock option to one newly-hired employee to purchase a total of 40,000 shares of the company's common stock at an exercise price per share of $7.74, which was the closing price per share of the company's common stock as reported by nasdaq on the grant effective date of march 1, 2024. the option was approved by the compensation committee of the company's board of directors and granted under the company's amended and restated inducement equity plan as an inducement material to the new employees entering into employment with the company in accordance with nasdaq listing rule 5635(c)(4). the option vests over four years, with 25% vesting on the one-year anniversary of the grant date and the remaining 75% percent vesting in approximately equal monthly installments over the following thirty-six months, subject to the employee being continuously employed by the company through each vesting date.
FATE Ratings Summary
FATE Quant Ranking